Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3MAYQ)

Drug Name
BMS-986205 Drug Info
Synonyms
KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Gastric adenocarcinoma 2B72 Phase 2 [1]
Renal cell carcinoma 2C90 Phase 2 [1]
Advanced cancer 2A00-2F9Z Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
121328278
CAS Number
CAS 1923833-60-6
TTD Drug ID
DM3MAYQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Indoleamine 2,3-dioxygenase 1 (IDO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Tryptophan DMIBH7M Depression 6A70-6A7Z Approved [2]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [3]
INCB24360 DMIJGT9 Urothelial carcinoma 2C92.0 Phase 3 [4]
NLG8189 DM0798Z Melanoma 2C30 Phase 2/3 [1]
DN1406131 DMQFX8R Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
HTI-1090 DMI4TEC Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
KHK2455 DMLSUQ8 Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
LY3381916 DMONZ1L Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
PF-06840003 DMOX6EJ Glioma 2A00.0 Phase 1 [7]
NLG802 DMP9J5V Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Indoleamine 2,3-dioxygenase 1 (IDO1) TTZJYKH I23O1_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
3 Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
4 Incyte. Product Development Pipeline.
5 ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
6 Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)